Study title:
Baumgartner-Matthias-R, Dantas-M-Fernanda, Suormala-Terttu, Almashanu-Shlomo, Giunta-Cecilia, Friebel-Dolores, Gebhardt-Boris, Fowler-Brian, Hoffmann-Georg-F, Baumgartner-E-Regula, Valle-David.
Division of Metabolism and Molecular Pediatrics, University Children's Hospital, Zurich, Switzerland..
Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant negative effect and responsiveness to biotin therapy.
American journal of human genetics, {Am-J-Hum-Genet}, Nov 2004 (epub: 09 Sep 2004), vol. 75, no. 5, p. 790-800, ISSN: 0002-9297.Baumgartner-Matthias-R, Dantas-M-Fernanda, Suormala-Terttu, Almashanu-Shlomo, Giunta-Cecilia, Friebel-Dolores, Gebhardt-Boris, Fowler-Brian, Hoffmann-Georg-F, Baumgartner-E-Regula, Valle-David.
Division of Metabolism and Mo...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Nutritional and Metabolic Diseases [C18]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: BIOTIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|